Zentiva sets strategy as it starts out alone
Ensuring that Zentiva has the necessary strategy, skills, competencies, capabilities and people to operate independently as a “leading European generics player” is a key priority, the company’s head, Patrick Aghanian, told Generics bulletin as the firm started life as an independent company under the ownership of private-equity investor Advent International.
You may also be interested in...
After seemingly stabilizing late last year, Sanofi has seen its generics sales once again drop in the first quarter of 2020, despite moving past unfavorable prior-year comparisons with the Zentiva generics business which the company divested in 2018.
Reporting its fourth-quarter and full-year 2019 results, Sanofi saw an overall drop in generics sales following 2018’s divestment of Zentiva in Europe but enjoyed consistent turnover in emerging markets. Moreover, fourth-quarter generics turnover showed a stabilization of the business once the Zentiva comparison is removed.
Mylan has moved up to become the world’s leading generics, biosimilars and OTC player, according to Generics Bulletin’s newly compiled global rankings. Sandoz has surpassed troubled Teva into second spot, but is set to surrender that position once it sells its US solid-dose and dermatology business to India’s Aurobindo, which has already moved into the global top 10.